Cannara Biotech Inc. has shown modest price movement this week, driven by strategic financial developments.
Cannara Biotech Inc. (LOVE.TO) has experienced a slight uptick of 1.53% over the past week, closing at C$1.99. The company has been in the news recently due to its expansion of financing options and its positioning in the cannabis sector. Let's delve into what this means for investors and the company's technical outlook.
Advertisement
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$205.47M
P/E
18.9x
52W high
$2.37
52W low
$1.55
1W change
+0.48%
Beta
0.27
Analyst Price Targets
Based on analyst covering LOVE · as of Sep 17, 2026
Wall Street analysts forecast LOVE stock price to fall 76.9% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
-76.9% Upside
Current Price
C$14.58
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
29.3%
Annualized
90-Day Vol
32.7%
Annualized
Trend (90d)
+39.6%
Annualized drift
90d Mean
C$2.43
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.21 | C$2.00 – C$2.45 |
| 60 trading days | C$2.32 | C$2.01 – C$2.67 |
| 90 trading days | C$2.43 | C$2.04 – C$2.90 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Cannara Biotech's recent financing expansion signals a commitment to growth, but investors should remain cautious given the stock's current performance relative to its historical range.
Cannara Biotech's stock has a P/E ratio of 18.09 and a market cap of approximately C$196.6 million.
With a profit margin of 9.3% and an EPS of 0.11, Cannara is maintaining a solid financial position, which could attract investor interest if growth continues.
Bull case
The expansion of financing to an $80 million syndicated credit facility shows that Cannara has a strong financial base. This move could open doors for future growth and investment opportunities, making it an attractive option for investors looking for potential in the cannabis market.
Bear case
Despite the recent positive news, Cannara's stock is still near the lower end of its 52-week range. This suggests that it may struggle to gain significant upward momentum in the near future, which could be a concern for investors.
Recent Company News
Cannara Biotech has recently expanded its financing to an $80 million syndicated credit facility with BMO and TD Bank. This strategic move is aimed at strengthening its financial foundation for continued growth in the cannabis sector. Additionally, the company was highlighted in a recent article discussing three Canadian penny stocks to consider in September 2026, further drawing attention to its potential in the market.
Advertisement
Technical Picture
The current trading price of C$1.99 is above both the 50-day moving average of C$1.93 and the 200-day moving average of C$1.81, indicating a positive short to medium-term trend. The stock has traded within a 52-week range of C$1.55 to C$2.07, currently sitting at 85% of this range. With a beta of 0.36, Cannara's stock has shown lower volatility compared to the market, which may appeal to conservative investors. The latest volume of 44,362 shares is slightly above the 20-day average volume of 35,323 shares, suggesting a modest increase in trading activity.
Insider Activity
Currently, there is no reported insider trading activity for Cannara Biotech Inc., which may indicate stability in the company's leadership and no immediate concerns from insiders regarding the stock's performance.
Price Action Summary
Cannara Biotech Inc. closed at C$1.99, reflecting a 0.00% change for the day and a 1.53% increase over the week. The stock has shown a year-to-date increase of 8.15%, suggesting a gradual upward trend despite recent fluctuations.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
